In this article we will take a look at the 5 best biotech stocks under $6 in 2021. For a detailed analysis of the biotech industry, go directly to the 10 Best Biotech Stocks Under $6 in 2021.
5. Seelos Therapeutics, Inc. (NASDAQ: SEEL)
Number of Hedge Fund Holders: 4
Price as of April 19, 2021: $5.00 per share
Seelos Therapeutics, Inc. (NASDAQ: SEEL) is a New York-based biotech firm that develops and sells drugs related to treatment of the central nervous system, respiratory, and other disorders. The products that the company markets include SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders. It also makes SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis, and SLS-006, a dopamine for Parkinson’s disease.
The company has a market cap of more than $411 million and posted an annual revenue of more than $375,000 in the fourth quarter of 2019. It was founded in 2016 and is placed fifth on our list of 10 best biotech stocks under $6 in 2021. Out of the hedge funds being tracked by Insider Monkey, New York-based Renaissance Technologies holds the most shares in the firm – 702,486 – worth more than $1.1 million. Citadel Investment Group was second on the list with 77,814 shares worth $0.12 million.
4. Dyadic International, Inc. (NASDAQ: DYAI)
Number of Hedge Fund Holders: 5
Price as of April 19, 2021: $4.85 per share
Dyadic International, Inc. (NASDAQ: DYAI) is a Florida-based global biotechnology company. Dyadic concentrates on the improvement and application of a proprietary C1 expression system to help developers and manufacturers bring drugs to the market. It also works on making vaccines and drugs related to antigens, monoclonal antibodies, and fab antibody fragments. Dyadic has a drug in a clinical trial that is slated to help in the development of a new generation of COVID-19 vaccines. The firm is fourth on our list of 10 best biotech stocks under $6 in 2021
Dyadic has signed research and development deals with several companies around the world, including the VTT Technical Research Centre of Finland, the Biotechnology Developments for Industry in Pharmaceuticals, Jiangsu Hengrui Medicine, and Serum Institute of India. The company was founded in 1979. At the end of the fourth quarter of 2020, 5 hedge funds in the database of Insider Monkey held stakes worth $0.9 million in the firm, up from 4 in the preceding quarter.
3. Eyenovia, Inc. (NASDAQ: EYEN)
Number of Hedge Fund Holders: 4
Price as of April 19, 2021: $4.86 per share
Eyenovia, Inc. (NASDAQ: EYEN) is a New York-based biotechnology firm that uses proprietary microdose array print (MAP) platform technology to develop therapeutics. The company is focusing on the development of therapeutic indications for patients with progressive myopia and age-related near vision impairment, as well as other eye-related problems. It also has a drug named MicroLine in the pipeline, which, if it passes clinical trials, will help the improvement of near vision in people with presbyopia.
Another drug under development is MicroPine, which is in Phase III clinical development and will help people with pediatric myopia progression. The firm has already signed a deal with Bausch Health Ireland Limited to develop and sell MicroPine in the United States and Canada. It is placed third on our list of 10 best biotech stocks under $6 in 2021. Out of the hedge funds being tracked by Insider Monkey, Chicago-based Fairpointe Capital holds the most shares in the firm – 209,526 – worth more than $1.2 million.
2. MediWound Ltd. (NASDAQ: MDWD)
Number of Hedge Fund Holders: 2
Price as of April 19, 2021: $4.91 per share
MediWound Ltd. (NASDAQ: MDWD) is an Israel-based company that concentrates on the development and manufacture of therapeutics based on a patented proteolytic enzyme technology. These therapeutics are used to treat severe burns, chronic and other wounds. One of the drugs made by the firm, called NexoBrid, is used for the removal of eschar, a dead or damaged tissue in adults. MediWound also makes EscharEx, a drug that treats chronic and other wounds and is currently in advanced clinical trials.
MediWound Ltd. was founded in 2000 and is placed second on our list of 10 best biotech stocks under $6 in 2021. In December 2020, the firm entered into an agreement with a UAE company for the marketing and selling of NexoBrid in the Middle Eastern market. The regulatory approval for the drug that treats severe burns is expected to be granted within a year. At the end of the fourth quarter of 2020, 2 hedge funds in the database of Insider Monkey held stakes worth $2.5 million in the firm, the same as in the preceding quarter having stakes worth $2.4 million.
1. Amarin Corporation plc (NASDAQ: AMRN)
Number of Hedge Fund Holders: 24
Price as of April 19, 2021: $5.04
Amarin Corporation plc (NASDAQ: AMRN) is an Ireland-based company that develops and sells medicines for the treatment of cardiovascular disease. One of the products that the company offers is the drug Vascepa, a prescription grade omega-3 fatty acid that competes against similar drugs made by bigger biotech firms. Amarin sells the medicines it makes to wholesale dealers and pharmacy providers. It was founded in 1989 and is placed first on our list of 10 best biotech stocks under $6 in 2021.
The firm is in partnership with Mochida Pharmaceutical Co., Ltd. to develop and sell drug products based on Vascepa. The Irish firm posted an annual revenue of more than $600 million in December 2020. Amarin was previously known as Ethical Holdings plc but changed the name to Amarin Corporation plc in 1999. Out of the hedge funds being tracked by Insider Monkey, New York-based Baker Bros. Advisors hold the most shares in the firm – 27.9 million – worth more than $136 million. Eversept Partners was second with shares worth $78 million.
You can also take a peek at 10 Best Biotech Stocks To Buy For 2021, and Top 10 Best Freelancing Platforms and Websites for 2021.
